The FDA has approved Takeda’s Fruzaqla for a group of patients with relapsed or refractory metastatic colorectal cancer, offering another option for patients who have exhausted earlier lines of therapy.
Takeda said that Fruzaqla (fruquintinib) has been cleared for use in adults with CRC who have been previously treated with chemotherapy, an anti-VEGF drug, and – if appropriate – an anti-EGFR therapy.
